Company intelligence / Profile preview
Aviceda Therapeutics
Cambridge, Massachusetts, United Statesavicedarx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AVD-104 has demonstrated positive safety and early clinical efficacy in patients with geographic atrophy secondary to AMD. In Part I of the Phase II/III SIGLEC trial, AVD-104 was well-tolerated with no drug-related serious adverse events. Substantial slowing of GA lesion growth and functional improvement were observed at three months after a single dose. The pivotal Part II trial is fully enrolled; primary endpoint data are expected in late-2025[10][7].
- Therapeutic areas
- OphthalmologyImmunologyOtherOncologyNeurology
- Modalities
- glycan-coated nanoparticlesimmunomodulatorsglycobiology-based therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Aviceda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aviceda Therapeutics.